44 results about "Borrelia burgdorferi" patented technology

The invention relates to a loop-mediated isotheral amplification method (LAMP) for detecting Lyme disease pathogen in tick bodies, which is characterized by taking 16S rRNA gene as the target gene, using special software to design the LAMP for detecting the primers of the Lyme disease pathogen-Borrelia burgdorferi in the tick bodies, then selecting the primer of the specific fragment of the Lyme disease pathogen from the primers, extracting DNA after piercing the ticks to be detected, uniformly mixing the obtained DNA and the reaction buffer, the reaction mixture of the selected primer of the specific fragment and DNA polymerase to carry out amplification, adding loading buffer after activating the amplified product, then placing the mixture into agarose gel containing ethidium bromide to carry out electrophoresis detection and detecting whether the detected ticks carry the Lyme disease pathogen according to whether the specific band occurs after electrophoresis.

The invention discloses a protein chip for lyme disease flagellin antigen immunoserology diagnosis and a preparation method and application of the protein chip. The protein chip is characterized in that borrelia burgdorferi recombination flagellin antigen probes are fixed on the surface of a solid phase carrier in a dot matrix mode; the solid phase carrier is a 16-amino-1-hexadecyl mercaptan modified gold foil chip which is combined with 4-(N-maleinimide methyl) cyclohexane-1-carboxylic acid succinimide ester and 4-(dimethylamino) pyridine. The protein chip disclosed by the invention can accurately detect an anti-flagellin antigen IgG antibody and an anti-flagellin antigen IgM antibody in serums of lyme disease patients, the operation is simple, and the detection result is stable.

The present invention provides methods and compositions for determining the presence and/or amount of Borrelia burgdorferi nucleic acids in a test sample related to Lyme disease. In particular, substantially purified oligonucleotide primers and probes are described that can be used for qualitatively and quantitatively detecting Borrelia burgdorferi nucleic acid in a test sample by amplification methods. The present invention also provides primers and probes for generating and detecting control nucleic acid sequences that provide a convenient method for assessing internal quality control of the Borrelia burgdorferi assay.

A method for diagnosing Lyme disease status in a mammal is provided. The method entails, in a biological sample obtained or derived from a mammal, determining antibodies to Borrelia burgdorferi (B. burgdorferi) outer surface proteins (Osp) OspA, OspC, and OspF. Based upon determining the OspA, OspC, and OspF antibodies, the mammal can be diagnosed as vaccinated, not vaccinated, infected or not infected with B. burgdorferi. Mammals that have early, intermediate or chronic B. burgdorferi infection can also be identified. The method is particularly suited for use with horses and dogs. Isolated or recombinant B. burgdorferi antigens and compositions that contain them are also provided.

The invention belongs to the field of biomedicine detection, and particularly relates to a protein chip modified by succinyl-beta-cyclodextrin for detecting lyme disease and preparation and application of the protein chip. On the one hand, the invention provides a protein chip for detecting the lyme disease, comprising a solid phase carrier and a capture molecule fixed on the solid phase carrier, wherein the capture molecule contains a principal protein-like sequence expression E protein (VisE) of borrelia burgdorferi variable. In detection, each chip can detect multiple serum samples simultaneously, and is relatively high in flexibility and specificity, so that the occurrence probability of false positive detection and false negative detection among groups is reduced. Compared with a traditional method, the protein chip is applied to screening population at high-risk areas on a large scale; relatively simple, convenient and reliable detection methods can be provided; the screening efficiency as well as the positive detecting rate and accuracy are enhanced.

The invention discloses a Taqman real-time fluorescence PCR detection method for detecting Borrelia burgdorferi nucleic acid, belonging to the technical field of biological detection. The Taqman real-time fluorescence PCR detection method disclosed by the invention applies a pair of Borrelia burgdorferi specific primers (SEQ ID NO. 1 and SEQ ID NO. 2 ) and a fluorescently labeled probe (SEQ ID NO. 3) for real-time fluorescence PCR amplification and detection of a fluorescence signal of an amplification product, so as to determine whether a sample carries Borrelia burgdorferi pathogen. The detection method is easy, rapid, sensitive, accurate and specific. The fluorescence probe which is complementary to and paired with a template enhances the specificity and effectively prevents false positives and false negatives. During detection, the fluorescence signals are collected automatically to avoid human factor interference in electrophoretic analysis after common PCR reaction, and a detection process is completely closed, without post-treatment such as electrophoresis, thereby eliminating the pollution of PCR products. The detection method disclosed by the invention has the characteristics of high specificity and good stability.

The invention discloses an LAMP primer combination for detecting three ophthalmic infection spirochetes and application. The primer combination is composed of eighteen single-stranded DNA molecules shown from the sequence 1 to the sequence 18. The invention further provides application of the primer combination. The invention furthermore provides a method of using the primer combination for identifying whether a spirochete to be detected is treponema pallidum, or borrelia burgdorferi or leptospira, a method for identifying whether the spirochete to be detected is treponema pallidum, or borrelia burgdorferi or leptospira and a method for identifying whether a sample to be detected is infected by treponema pallidum and/or borrelia burgdorferi and/or leptospira. Treponema pallidum, borrelia burgdorferi and leptospira can be fast and accurately detected by using the method.

A bacterin including effective immunizing amounts of two non-crossprotective isolates of inactivated Borrelia burgdorferi, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated Borrelia burgdorferi isolates and a suitable carrier is provided herein. The bacterin may also contain a third non-crossprotective isolate. A bacterin including effective immunizing amounts of an antigenic subunit derived from a first Borrelia burgdorferi isolate and a second, non-crossprotective Borrelia burgdorferi isolate, an adjuvant in an amount effective to enhance the immunogenicity of the antigenic subunits and a suitable carrier is also provided. The bacterin may also contain an effective immunizing amount of an antigenic subunit of a third Borrelia burgdorferi. Further provided is a bacterin which includes effective immunizing amounts of two noncrossprotective isolates of inactivated Borrelia burgdorferi and one or more antigenic subunits from the non-crossprotective isolates, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated Borrelia burgdorferi and antigenic subunits and a suitable carrier.

The invention belongs to the field of biomedicine detection and particularly relates to a protein combined chip for Lyme disease immunoserology diagnosis and a preparation method and application thereof. The protein combined chip comprises a solid phase carrier and capture molecules fixed to the surface of the solid phase carrier, and the capture molecules comprise Borrelia burgdorferi flagellin, Borrelia burgdorferi outer membrane protein C (OspC) and Borrelia burgdorferi variable main protein sequence expression E protein (VlsE). The protein combined chip can further comprise capture molecules VlsE IR6 polypeptide. Compared with a traditional method, the protein combined chip can conveniently distinguish infection types on the basis of greatly increasing the positive rate.

The instant invention provides an immunogenic composition comprising an antigenic fragment of OspA protein of Borrelia burgdorferi and a chimeric protein containing antigenic fragments of different phylotypes of OspC protein of Borrelia burgdorferi. Vaccines incorporating the immunogenic composition of the invention, as well as methods of preventing Lyme disease in dogs and/or protecting dogs from Lyme disease using the vaccines are also provided.

The invention achieves the purpose by providing a novel modeling method of rat rheumatoid arthritis. On the basis of the conventional incomplete Freund's adjuvant, recombinant Borrelia burgdorferi P100 protein and CGCpGGC oligonucleotide are combined together for a modeling experiment of a rheumatoid animal model of a Lewis rat so as to establish a stable and high-efficiency novel modeling method. Due to the adoption of the modeling method, the modeling success rate is 88.89% or above, a foundation is laid for studying and developing a medicine for treating the rheumatoid arthritis, and the purpose of stably and efficiently preparing the rheumatoid arthritis animal model of the rat is achieved.

The invention belongs to the technical field of biological detection and in particular relates to a PCR (Polymerase Chain Reaction) detection primer and a detection method for borrelia burgdorferi. By extracting borrelia burgdorferi nucleic acid, a pair of borrelia burgdorferi specific primers SEQ ID NO.1 and SEQ ID NO.2 are subjected to PCR amplification; an amplified product is subjected to electrophoresis on lipolysaccharide gel through utilizing a TAE buffering solution; a PCR product is observed under an ultraviolet projector and is compared with a standard molecular weight, so as to judge whether a sample carries a borrelia burgdorferi pathogen or not: if an electrophoretogram has a 225bp specific strip, the electrophoretogram shows that the sample carries the borrelia burgdorferi pathogen; if the electrophoretogram has no 225bp specific strip, the electrophoretogram shows that the sample does not carry the borrelia burgdorferi pathogen. Detection verifies that a detection system provided by the invention has the characteristics of high specificity and good stability.

Two Borrelia burgdorferi recombinant proteins were expressed in E. coli. These two proteins were generated from (a) the full length dbpA gene combined with the invariable region 6 of the VlsE gene (dbpA/C6), and (b) the full length OspC gene combined with the coding sequence for amino acids 1-121 of the E. coli maltose binding protein gene (OspC/MBP). Methods of using these recombinant proteins for detecting anti-Borrelia burgdorferi antibodies in patient sera and diagnosis of Lyme Disease are described.

In this application is described the characterization Borrelia burgdorferi lipoprotein BBK07, an in vivo expressed and surface-exposed immunogen. BBK07 expression in the infected hose can be detected at the RNA and protein level as early as the first week of infection. Therefore, described is the use of BBK07 antigen and immunogenic epitopes as well as bbk07 nucleotides in methods and kits for the diagnosis of Lyme disease.

The invention relates to preparation and application of a borrelia burgdorferi flagellin FlaB antibody. By means of a PCR method, a gene segment of FlaB is obtained from a borrelia burgdorferi genomethrough amplification, cloned into a prokaryotic expression vector pET30a containing a histidine tag and then transferred into escherichia coli BL21 competent cells. Induction expression is carried out through IPTG, affinity purification is performed to obtain FlaB protein, immunized mice obtain the borrelia burgdorferi flagellin FlaB antibody, and a solid foundation is laid for detection and deepresearch of borrelia burgdorferi.

The present invention relates to a treatment for mammalian subjects suffering from a central nervous system (CNS) disorder by administering a composition comprising an Borrelia burgdorferi antigen at a sub-vaccine level effective to alleviate symptoms of the CNS disorder.